Rejoni, a Bedford, MA-based company focused on the development and commercialization of gynecological products using its proprietary biomaterials, raised $25M in Series B funding.
The round was led by Catalyst Health Ventures, with continued support from Ascension Health Ventures, Delos Capital, Sparta Group, Amed Ventures, and Iyengar Capital Partners. Darshana Zaveri, Founder & Managing Partner at Catalyst Health Ventures, will also be joining Rejoni’s Board of Directors.
Led by CEO Amar Sawhney, Rejoni is advancing the Juveena Hydrogel System (HS), which is currently undergoing clinical investigation under an IDE pivotal study in the United States. The Juveena HS is being developed for use as a temporary implant to prevent the intrauterine adhesions (IUA) that can form inside the uterine cavity following transcervical gynecological procedures.
The proceeds from this round will be used to complete this landmark study as well as continue to explore additional therapeutic indications in Women’s Health.
FinSMEs
07/12/2022